A new immuno-oncology target - SUMOylation.

ABSTRACT: Immunotherapy has been a paradigm shift in cancer treatment to produce durable responses. Unfortunately, most cancers do not respond to current immunotherapies, and thus, exploring novel mechanisms is crucial. Emerging data now demonstrate that protein modification by the small ubiquitin-like modifiers (SUMO) is a novel target to activate antitumor immunity.

SUBMITTER: Chen Y 

PROVIDER: S-EPMC10911497 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature